【レポートの概要（一部）】
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Overview: Immunotherapy
• Types of immunotherapy
• Key events
• Reimbursement policies
• Orphan drug designation and regulatory approvals
PART 06: Pipeline portfolio
• Anticipated number of immuno-oncology pipeline assets with single and multiple indications by 2020
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Market segmentation by type of immunotherapy
• mAbs
• Immune checkpoint inhibitors
• Vaccines
• Non-specific immunotherapies
PART 09: Market segmentation by therapy area
PART 10: Geographical segmentation
• Global immunotherapy drugs market by geographical segmentation 2015-2020
• Immunotherapy drugs market in Americas
• Immunotherapy drugs market in EMEA
• Immunotherapy drugs market in APAC
PART 11: Market drivers
• Growing prevalence of cancer and autoimmune diseases
• Rise in older population
• Increase in demand for mAbs
• Patient assistance programs
• Promising pipeline
PART 12: Impact of drivers
PART 13: Market challenges
• Patent expiries of top-selling drugs
• High costs of biologicals
• Poor diagnosis and screening
• Adverse effects
• Stringent regulations
PART 14: Impact of drivers and challenges
PART 15: Market trends
• Increase in awareness programs
• Emergence of targeted and combination therapies
• Emergence of biosimilars
• Strategic alliances
• Expected entry of novel vaccines
PART 16: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• F. Hoffmann-La Roche
• AbbVie
• Johnson & Johnson
• Merck
• Amgen
• BMS
• Other prominent vendors
PART 17: Appendix
• List of abbreviations
PART 18: Explore Technavio
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: Types of immunotherapy
Exhibit 03: Key events in discovery and approvals of immunotherapy drugs
Exhibit 04: Immunotherapy drugs approved by US FDA in 2015
Exhibit 05: US FDA orphan drug designations and approvals list for immunotherapy drugs
Exhibit 06: EU orphan drug designations and approvals list for immunotherapy drugs
Exhibit 07: Phase III pipeline molecules for mAbs
Exhibit 08: Phase II pipeline molecules for mAbs
Exhibit 09: Phase I pipeline molecules for mAbs
Exhibit 10: Pipeline molecules for immune checkpoint inhibitors
Exhibit 11: Phase III pipeline molecules for vaccines
Exhibit 12: Phase II pipeline molecules for vaccines
Exhibit 13: Phase I pipeline molecules for vaccines
Exhibit 14: Near-launch immuno-oncology pipeline assets
Exhibit 15: Global immunotherapy drugs market 2015-2020 ($ billions)
Exhibit 16: Factors influencing global immunotherapy drugs market
Exhibit 17: Challenges faced by US immunologists while prescribing immunotherapy drugs 2015
Exhibit 18: SWOT analysis of global immunotherapy drugs market
Exhibit 19: Five forces analysis
Exhibit 20: Market segmentation by type of immunotherapy drug
Exhibit 21: Timeline of mAbs approval for cancer by US FDA
Exhibit 22: Timeline of mAbs approval for autoimmune, respiratory, and ophthalmic diseases by US FDA
Exhibit 23: Global mAbs market 2015-2020 ($ billions)
Exhibit 24: Key drivers and challenges of global monoclonal antibodies drugs market
Exhibit 25: Top vendor offerings in global mAbs market
Exhibit 26: Global immune checkpoint inhibitors market 2015-2020 ($ billions)
Exhibit 27: Key driver and challenge for global immune checkpoint inhibitors market
Exhibit 28: Top vendor offerings in global immune checkpoint inhibitors market
Exhibit 29: Global vaccines market 2015-2020 ($ billions)
Exhibit 30: Segmentation of global vaccines market by application 2015
Exhibit 31: Key drivers and challenges of global vaccines market
Exhibit 32: Top vendor offerings in global vaccines market
Exhibit 33: Global non-specific immunotherapies market 2015-2020 ($ billions)
Exhibit 34: Key drivers and challenges of global non-specific immunotherapies market
Exhibit 35: Top vendor offerings in global non-specific immunotherapies market
Exhibit 36: Segmentation of global immunotherapy drugs market by type of immunotherapy 2015
Exhibit 37: Global immunotherapy drugs market; YoY revenue and growth rate based on type of immunotherapy 2015-2020 ($ billions)
Exhibit 38: Global immunotherapy drugs market segmentation by therapy area
Exhibit 39: Segmentation of global immunotherapy drugs market by therapy area 2015
Exhibit 40: Segmentation of global immunotherapy drugs market by geography 2015
Exhibit 41: Global immunotherapy drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 42: Immunotherapy drugs market in Americas 2015-2020 ($ billions)
Exhibit 43: Market share in the Americas by type of immunotherapy 2015
Exhibit 44: Immunotherapy drugs market in EMEA 2015-2020 ($ billions)
Exhibit 45: Market share in Europe by type of immunotherapy 2015
Exhibit 46: Immunotherapy drugs market in APAC 2015-2020 ($ billions)
Exhibit 47: Market share in APAC by type of immunotherapy 2015
Exhibit 48: Global immunotherapy drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 49: Global incidence of cancers 2015 and 2020
Exhibit 50: Population aged 60 years and over: World, developed, and developing regions (millions)
Exhibit 51: Patient assistance programs for immunotherapy drugs
Exhibit 52: Some pipeline molecules for immunotherapy drugs
Exhibit 53: Impact of drivers
Exhibit 54: Approvals and patent expiries of top-selling immunotherapy drugs
Exhibit 55: Average annual treatment cost per patient for some immunotherapy drugs 2014 ($ millions)
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Expected combination regimen launches in immune-oncology 2015-2020
Exhibit 58: Market share analysis of top vendors0
Exhibit 59: Competitive assessment of top 10 immunotherapy drugs 2015 ($ billions)1
Exhibit 60: YoY sales comparison of top five immunotherapy drugs 2013-2015 ($ billions)1
Exhibit 61: F. Hoffmann-La Roche: Immunotherapy drugs segmentation by revenue 20152
Exhibit 62: F. Hoffmann-La Roche: Top-selling immunotherapy drugs 20152
Exhibit 63: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions)
Exhibit 64: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)4
Exhibit 65: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)5
Exhibit 66: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 20155
Exhibit 67: F. Hoffmann-La Roche: MabThera/Rituxan geographic segmentation by revenue 20156
Exhibit 68: F. Hoffmann-La Roche: YoY revenue and growth rate of Avastin 2012-2015 ($ billions)7
Exhibit 69: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin 2012-2015 ($ billions)8
Exhibit 70: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in US 2013-2015 ($ billions)8
Exhibit 71: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in EU 2013-2015 ($ billions)8
Exhibit 72: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in Japan 2013-2015 ($ millions)9
Exhibit 73: F. Hoffmann-La Roche: YoY revenue and growth rate of Perjeta 2012-2015 ($ billions)0
Exhibit 74: F. Hoffmann-La Roche: YOY revenue and growth rate of Kadcyla 2013-2015 ($ billions)1
Exhibit 75: F. Hoffmann-La Roche: Key takeaways3
Exhibit 76: AbbVie: Immunotherapy drugs segmentation by revenue 20154
Exhibit 77: AbbVie: YoY revenue and growth rate of HUMIRA 2013-2015 ($ billions)5
Exhibit 78: AbbVie: YoY revenue and growth rate of HUMIRA in US 2013-2015 ($ billions)5
Exhibit 79: AbbVie: YoY revenue and growth rate of HUMIRA in ROW 2013-2015 ($ billions)5
Exhibit 80: AbbVie: Sales of HUMIRA in major markets 20156
Exhibit 81: AbbVie: Key takeaways7
Exhibit 82: Johnson & Johnson: Key immunotherapy drugs segmentation by revenue 20158
Exhibit 83: Johnson & Johnson: Top-selling immunotherapy drugs 20158
Exhibit 84: Johnson & Johnson: YoY revenue and growth rate of Remicade 2012-2015 ($ billions)9
Exhibit 85: Johnson & Johnson: YoY revenue and growth rate of Stelara 2012-2015 ($ billions)0
Exhibit 86: Johnson & Johnson: YoY revenue and growth rate of Stelara in US 2012-2015 ($ billions)0
Exhibit 87: Johnson & Johnson: YoY revenue and growth rate of Stelara in ROW 2012-2015 ($ millions)0
Exhibit 88: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2012-2015 ($ billions)1
Exhibit 89: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in the US 2012-2015 ($ billions)1
Exhibit 90: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in ROW 2012-2015 ($ billions)2
Exhibit 91: Johnson & Johnson: Key takeaways3
Exhibit 92: Merck: Business segmentation by revenue 20154
Exhibit 93: Merck: Immunotherapy drugs segmentation by revenue 20155
Exhibit 94: Merck: Top-selling immunotherapy drugs 20156
Exhibit 95: Merck: YoY revenue and growth rate of Gardasil/Gardasil9 2012-2015 ($ billions)7
Exhibit 96: Merck: YoY revenue and growth rate of ProQuad/M-M-R II/Varivax 2012-2015 ($ billions)8
Exhibit 97: Merck: YoY revenue and growth rate of Zostavax 2012-2015 ($ millions)8
Exhibit 98: Merck: YoY revenue and growth rate of Pneumovax 23 2012-2015 ($ millions)9
Exhibit 99: Merck: YoY revenue and growth rate of RotaTeq 2012-2015 ($ millions)9
Exhibit 100: Merck: Key takeaways2
Exhibit 101: Amgen: Top-selling immunotherapy drugs 20153
Exhibit 102: Amgen: YoY revenue and growth rate of Enbrel in US and Canada 2012-2015 ($ billions)4
Exhibit 103: Amgen: YoY revenue and growth rate of Enbrel in US 2012-2015 ($ billions)4
Exhibit 104: Amgen: YoY revenue and growth rate of Enbrel in Canada 2012-2015 ($ millions)4
Exhibit 105: Amgen: YoY revenue and growth rate generated from net product sales of Xgeva 2012-2015 ($ billions)5
Exhibit 106: Amgen: YoY revenue and growth rate generated from net product sales of Prolia 2012-2015 ($ billions)5
Exhibit 107: Amgen: YoY revenue and growth rate of Vectibix in US 2012-2015 ($ millions)6
Exhibit 108: Amgen: YoY revenue and growth rate of Vectibix in ROW 2012-2015 ($ millions)6
Exhibit 109: Amgen: Key takeaways9
Exhibit 110: BMS: Business segmentation by revenue 20150
Exhibit 111: BMS: Immunotherapy drugs segmentation by revenue 20150
Exhibit 112: BMS: Top-selling immunotherapy drugs 20151
Exhibit 113: BMS: YoY revenue and growth rate of Orencia 2012-2015 ($ billions)2
Exhibit 114: BMS: YoY revenue and growth rate generated from net product sales of Yervoy 2012-2015 ($ billions)2
Exhibit 115: BMS: YoY revenue and growth rate of Erbitux in US, Canada, and Japan 2012-2015 ($ millions)3
Exhibit 116: BMS: Key takeaways
【レポート販売概要】
■ タイトル：免疫治療薬の世界市場：モノクローナル抗体、免疫チェックポイント阻害薬、ワクチン、非特異的免疫療法■ 英文：Global Immunotherapy Drugs 2016-2020
■ 発行日：2016年3月29日
■ 調査会社：Technavio
■ 商品コード：IRTNTR8772
■ 調査対象地域：世界
- 世界のサニタリーポンプ市場：サニタリー渦巻ポンプ、容積式ポンプ、特殊ポンプAbout Sanitary Pumps Sanitary pumps, also known as hygienic pumps, are used in a production line to initiate the flow of sensitive medium that is highly prone to contamination. Sanitary pumps find their application mainly in the Food and Beverage, and Pharmaceuticals and Personal Care industries, where the hygiene standards are provided at most importance. Sanitary pumps can be classified into cen …
- Cross Border Resources, Inc.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Cross Border Resources, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Cross Border Resources, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an es …
- 世界の固定ブロードバンド市場Global broadband market heading in the right directionThe global broadband market is heading in the right direction with both average broadband speeds going up - and broadband pricing, on the whole, coming down. This combined with the growing demand for fibre network infrastructure creates an environment that is full steam ahead for fixed broadband. With more than 100 countries now involved in the …
- グローバル軍事航空市場（2014-2024）：市場規模及び動因Synopsis This report provides readers with a comprehensive analysis of the Military Aviation market through 2014-2024, including highlights of the demand drivers and growth stimulators for Military Aviation. It also provides an insight on the spending pattern and modernization pattern in different regions around the world. Summary The global military aviation MRO market is estimated to value US$28 …
- Italian HIV/AIDS Diagnostics Market 2014: Hospitals, Blood Banks, Commercial Labs–Supplier Shares and Sales Forecasts For Immunodiagnostic and NAT ProceduresComplete report $2,300. DataPack (test volumes, sales forecasts, supplier shares) $1,500.Summary This report presents detailed analyses of the AIDS diagnostics market in Italy. The report provides test volume and sales forecasts for HIV-1/2, HIV Ag, NAT, Western Blot and other confirmatory tests performed in the following market segments: - Hospitals …
- 2014年戦略提言：フランスの血液凝固検査市場Complete report $6,100. DataPack (test volumes, sales forecasts, supplier shares) $3,950.SummaryThis comprehensive report contains 405 pages, 35 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the French coagulation testing market during the next five years. The report explores business and technol …
- 2014年戦略提言：アメリカの止血診断検査市場Complete report $9,600. DataPack (test volumes, sales forecasts, supplier shares) $6,200.SummaryThis comprehensive report contains 424 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the US coagulation testing market during the next five years. The report explores business and technologic …
- ジメチルエーテル（DME）の世界市場動向及び予測Dimethyl ether (DME) is an non-poisonous gas, which is liquefiable at a pressure of around 6 bars for storage purpose. It is used as a solvent in the petrochemical industry. The raw materials used in DME manufacturing process are coal, natural gas, bio-based feedstock and methanol. DME consist no sulfur content which gives an advantage of clean burning properties. It has various applications such …
- グーグルVS競合企業：コマース市場-ウォレット・システム（Google vs. Competitors: Commerce Market ? Wallet Systems）A battle is raging in the mobile commerce arena in the area of mobile payments. Google is battling against others literally for (electronic) wallet share. The stakes are high because whomever wins the battle for wallet share will have a huge advantage when it comes to actual mobile commerce. Payment solutions can be categorized on the basis of the payment settlement methods, which are instant-paid …
- 世界の医療産業におけるMEMS技術動向（2012-2016）TechNavio's analysts forecast the Global MEM Technology market in the Healthcare industry to grow at a CAGR of 34.8 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing need for high operating speed medical devices. The Global MEM Technology market in the Healthcare industry has also been witnessing the miniaturization of medical electronic de …
- 炭酸飲料の世界市場2015-2019About carbonated soft drinks The consumption of carbonated soft drinks is driven by consumers across all age groups owing to the indulgence and taste associated with these products. An increase in operational efficiency and massive urbanization in developing countries will drive the growth of the global carbonated soft drinks market during the forecast period. Technavio's analysts forecast the glo …
- 心臓補助装置：グローバル市場分析と予測MediPoint: Cardiac Assist Devices - Global Analysis and Market Forecasts Summary GlobalData has released its medical device report, “MediPoint: Cardiac Assist Devices - Global Analysis and Market Forecasts”. The report offers a comprehensive analysis of the global Cardiac Assist Device (CAD) Market, including development and sales in the Intra-Aortic Balloon Pump (IABP), Ventricular Assist Device …
- 世界のコンテンツ・セキュリティ・ゲートウェイ市場動向（2014-2018）TechNavio's analysts forecast the Global Content Security Gateway market to grow at a CAGR of 4.3 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing adoption of mobile devices. The Global Content Security Gateway market has also been witnessing the increasing popularity of cloud-based gateway solutions. However, the increasing complexity …
- RMP Energy Inc.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013RMP Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary RMP Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key ope …
- 細胞単離/細胞分離の世界市場：試薬、培地、血清、ビーズ、遠心機、フローサイトメーター、細胞分離装置The global market involves various products that help in separating specific cells from a tissue or a sample. This market is driven by several factors which include increasing usage of cell isolation in cancer research, increasing number of biotechnology and biopharmaceutical industries, technological advancements, high prevalence of infectious diseases, rising aging population, and growth in gove …
